Navigation Links
Notre Dame researchers offer new insights on cancer cell signaling
Date:7/15/2013

A pair of studies by a team of University of Notre Dame researchers led by Crislyn D'Souza-Schorey, professor of biological sciences, sheds light on a biological process which is activated across a vast range of malignancies.

Wnt proteins are a large family of proteins that active signaling pathways (a set of biological reactions in a cell) to control several vital steps in embryonic development. In adults, Wnt-mediated functions are frequently altered in many types of cancers and, specifically, within cell subpopulations that possess stem cell-like properties.

In two studies, one in the recent issue of the journal Molecular and Cellular Biology and a second, published earlier this year in Science Signaling, D'Souza-Schorey's laboratory reports on the importance of the protein "ARF6" in Wnt signaling.

The best documented role of Wnt is its triggering of the canonical (idealized or generalized) signaling pathway that leads to the stabilization of a protein called beta-catenin. This in turn leads to activation of various target genes that result in changes in a wide spectrum of cell behaviors.

"We have had a long standing interest in understanding the role of ARF6 in cell behavior," D'Souza-Schorey said. "ARF6 is an interesting molecule at the nexus of several important cell-signaling pathways. Our interest in this line of investigation has only been heightened by emerging reports from many labs that ARF6 activity is dramatically increased in several cancers. In our most recent study, we show how ARF6 can propagate Wnt signaling leading to proliferative phenotypes that are frequently seen in epithelial tumors (a growth of irregularly-shaped cells on the outer membrane of an organ or gland)."

In the paper published in Science Signaling, the laboratory collaborated with researchers at the University of Utah to document the importance of ARF6-regulated activation of canonical Wnt signaling in the spread of melanoma. The study showed that a small molecule that prevents ARF6 activation could stop tumor invasion and the spread of the cancer.

"The relevance of Wnt signaling in human cancers in manifest by the frequency with which this pathway is aberrantly activated across a wide range of malignancies," D'Souza-Schorey said. "Given the number of Wnts, Wnt signaling has been difficult to target therapeutically. It is important to note that while there are many mechanisms that drive aberrant Wnt/beta-catenin signaling in diverse cancers, these different mechanisms nearly always occur in a mutually exclusive manner. Thus, a better understanding of mechanisms involved in Wnt signaling transduction offers several target molecules for cancer drug development."

Notre Dame graduate students James Clancy, Oscar Pellon-Cardenas, Alanna Sedgwick and Henriette Uwimphuwe were co-authors on the two studies from D'Souza-Schorey's laboratory.


'/>"/>

Contact: Crislyn D'Souza-Schorey
cdsouzas@nd.edu
574-631-3735
University of Notre Dame
Source:Eurekalert

Related medicine news :

1. Notre Dame and Harper researchers developing novel method to test for HPV and oral cancers
2. New Notre Dame paper offers insights into how cancer cells avoid cell death
3. Notre Dame researchers scoring a win-win with novel set of concussion diagnostic tools
4. Notre Dame researchers paper examines the biology of tumor-derived microvesicles
5. Nanoparticles engineered at Notre Dame promise to improve blood cancer treatment
6. Use redistricting maps to make organ allocation more equitable, Johns Hopkins researchers advocate
7. Sanford-Burnham researchers develop novel nanoparticle to deliver powerful RNA interference drugs
8. Researchers investigate mechanism of Alzheimers therapy
9. Researchers pinpoint sources of fibrosis-promoting cells that ravage organs
10. Researchers use immunocytochemistry to determine ALK status
11. Researchers find 2 new methods to determine ALK status
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... June 27, 2016 , ... Quality metrics are proliferating in cancer care, ... remain in the eye of the beholder, according to experts who offered insights and ... Journal of Managed Care. For the full issue, click here . , For ...
(Date:6/26/2016)... , ... June 26, 2016 , ... Pixel Film Studios ... X. , "Film editors can give their videos a whole new perspective by using ... - CEO of Pixel Film Studios. , ProSlice Levels contains over 30 Different ...
(Date:6/26/2016)... NC (PRWEB) , ... June 26, 2016 , ... Brent Kasmer, a legally blind and ... to be personalized through a fitness app. The fitness app plans to fix the two ... currently only offer a one size fits all type program , They don’t ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... Miami, FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton ... Plant City Observer , brings up a new, often overlooked aspect of head lice: ... The closing for fumigation is not a common occurrence, but a necessary one in the ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... June 27, 2016  VMS Rehab Systems, Inc. ( ... take whatever measures required to build a strong and ... is currently listed on the OTC Markets-pink current trading ... and CEO, "We are seeing an anomaly in market ... not only by the Company, but shareholders and market ...
(Date:6/24/2016)... 2016  Consumers have taken a more active ... more emphasis on patient outcomes. ... the pharmaceutical industry have evolved beyond just providing ... are focusing on becoming more patient-oriented across their ... services that improve health. ...
(Date:6/24/2016)... June 24, 2016  Global Blood Therapeutics, Inc. (GBT) ... developing novel therapeutics for the treatment of grievous ... the closing of its previously announced underwritten public ... the public offering price of $18.75 per share. ... offered by GBT. GBT estimates net proceeds from ...
Breaking Medicine Technology: